Resonance Therapeutics (RTx) is an Australian medical technology company developing safe, effective, drug-free treatments for better mental health.
RTx is building a non-invasive neuromodulation system that can measure, analyse and stimulate the brain, providing uniquely personalised treatment for depression at-home.
Our team has been at the forefront of clinical brain stimulation research for over 20 years. Backed by research led by Professor Paul Fitzgerald and Professor Kate Hoy, having conducted numerous large clinical trials in device-based treatments in psychiatry and neuropsychology.
RTx spun out of Monash University in partnership with the neuromotion group, internationally established providers of high-performance neuroscience and clinical solutions, with 20 year track record of successfully bringing accredited software and medical grade devices to global markets.
PERSONALISED - OPTIMISED - PRECISE
Building devices that are the first of their kind, offering unique features and significant benefits over existing technologies.
Safe, non-invasive, drug-free
Providing cloud based tools for our users to remotely collect, monitor and interpret device and patient data.
Portable, scalable, at-home
Utilizing , machine learning and artificial intelligence to adapt, individualize and optimize patient outcomes.
Data driven, personalised , effective
How it Works
Integrated EEG measures brain-state at high resolutions
Powerful onboard signal processing extracts features in real-time
Stimulation is individualised in Phase, Frequency and Direction
CUTTING EDGE NEUROSCIENCE
DRUG FREE INTERVENTION
REAL TIME SIGNAL PROCESSING
BRAIN BASED STIMULATION
SIMPLE, EASY, HOME USE
INTERACTIVE AND ENGAGING
CLINICAL DESCISION SUPPORT
info at resonancetx.com